Identification of a Novel Mutation in Hereditary Breast Cancer in a Family with Wide Spectrum of Atypical Malignancies
Due to phenotypic variability, age-related penetrance, and variety of targeted organs, many families with an inherited cancer syndrome will not meet syndrome-specific criteria. We report hereditary breast cancer case in a family with gastric cancer, pancreatic cancer, lung sarcoma and penile cancer, suggesting several alternative hereditary cancer syndromes.
Mutation screening by NGS was performed using three panels with BRCA1, BRCA2, TP53, BMPR1A, SMAD4, CDH1, STK11, PTEN genes and 409 genes from Ion AmpliSeq Comprehensive Cancer Panel.
In maternal lineage we found a novel mutation c.5193_5194del:p.H1731fs in BRCA2 resulted in HBOC. 7 of 8 tested family members (87.5%) were carriers of the mutation; 4 would have been expected from mendelian ratio of 50%. In order to find out whether the paternal lineage could have another hereditary cancer syndrome we tested paternal uncle with penile carcinoma. 409 gene panel revealed no pathogenic mutations. VUS’s identified in this study cannot be used to make clinical decisions.
A positive cancer family history in itself is usually not enough to diagnose a cancer syndrome, especially when common type cancers are involved. Chance alone may cause the clustering of cancer (especially in large families) and the number of possible unaffected relatives.
1.Nagy R, Sweet K, Eng C. Highly penetrant hereditary cancer syndromes. Oncogene 2004;23:6445–70.
2. Thull D, Vogel V. Recognition and management of hereditary breast cancer syndromes. Oncologist 2004;9:13-24.
3. Beadling C, Neff TL, Heinrich MC, Rhodes K, Thornton M, Leamon J, et al. Combining highly multiplexed PCR with semiconductor-based sequencing for rapid cancer genotyping. J Mol Diagn 2013;15:171-6.
4. Garber JE, Offit K. Hereditary cancer predisposition syndromes. J Clin Oncol 2005;23:276-92.
5. Shulman LP. Hereditary breast and ovarian cancer (HBOC): clinical features and counseling for BRCA1 and BRCA2, Lynch syndrome, Cowden syndrome, and Li-Fraumeni syndrome. Obstet Gynecol Clin North Am 2010;37:109-33.
6. Iyevleva AG, Suspitsin EN, Kroeze K, Gorodnova TV, Sokolenko AP, Buslov KG, et al. Non-founder BRCA1 mutations in Russian breast cancer patients. Cancer Lett 2010;298:258-63.
7. Shinagare AB, Giardino AA, Jagannathan JP, Van den Abbeele AD, Ramaiya NH. Hereditary cancer syndromes: a radiologist's perspective. AJR Am J Roentgenol. 2011;197:W1001-7.
8. Silva AG, Krepischi AC, Pearson PL, Hainaut P, Rosenberg C, Achatz MI. The profile and contribution of rare germline copy number variants to cancer risk in Li-Fraumeni patients negative for TP53 mutations. Orphanet J Rare Dis 2014;9:63.
9. Chun N, Ford JM. Genetic testing by cancer site: stomach. Cancer J 2012;18:355-63.
10. Levy-Lahad E, Friedman E. Cancer risks among BRCA1 and BRCA2 mutation carriers. Br J Cancer 2007;96:11-5.
11. Mersch J, Jackson MA, Park M, Nebgen D, Peterson SK, Singletary C, et al. Cancers associated with BRCA1 and BRCA2 mutations other than breast and ovarian. Cancer 2015;121:269- 75.
12. Gronwald J, Gorski B, Byrski T, Huzarski T, Jakubowska A, Menkiszak J, Narod SA, Lubinski J. Non-random transmission of mutant alleles to female offspring of BRCA1 carriers in Poland. J Med Genet 2003;40:719-20.
13. Evans D, Shenton A, Sharif S, Woodward E, Lalloo F, Maheret E. Non-random transmission of mutant alleles to female offspring in BRCA carriers. J Med Genet 2005;42:e6.
14. de la Hoya M, Meijers-Heijboer H, Fernández JM, Díez O, Osorio A, Alonso C, et al. Mutant BRCA1 alleles transmis-sion: different approaches and different biases. Int J Cancer 2005;113:166-7.
15. Stanislaw C, Xue Y, Wilcox WR. Genetic evaluation and testing for hereditary forms of cancer in the era of next-generation sequencing. Cancer Biol Med 2016;13:55-67.
16. Tung N, Battelli C, Allen B, Kaldate R, Bhatnagar S, Bowles K, et al. Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel. Cancer 2015;121:25- 33.
17. Slavin TP, Niell-Swiller M, Solomon I, Nehoray B, Rybak C, Blazer KR, et al. Clinical Application of Multigene Panels: Challenges of Next-Generation Counseling and Cancer Risk Management. Front Oncol 2015;5:208.